Title:
CHIMERIC ANTIGEN RECEPTOR TARGETING GPRC5D, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/247756
Kind Code:
A1
Abstract:
Provided are a chimeric antigen receptor targeting G protein-coupled receptor C5 family subtype D (GPRC5D), and a preparation method and use therefor, especially the use thereof as an anti-cancer drug. The chimeric antigen receptor targeting GPRC5D includes extracellular antigen-binding domain. The extracellular antigen-binding domain includes a GPRC5D antibody light chain variable region and a GPRC5D antibody heavy chain variable region. A single-chain antibody (ScFv) that recognizes the tumor surface antigen GPRC5D is bound to a T cell activation domain and expressed in T cells, so as to recognize and bind the tumor surface antigen, induce T cell activation, secrete cytokines to kill tumor cells, which has a significant effect in the treatment of B lymphoma and acute lymphoblastic leukemia.
Inventors:
ZHAO RUIHUA (CN)
ZHANG JIQIN (CN)
DU BING (CN)
LIU MINGYAO (CN)
XI ZAIXI (CN)
ZHANG JIQIN (CN)
DU BING (CN)
LIU MINGYAO (CN)
XI ZAIXI (CN)
Application Number:
PCT/CN2022/094261
Publication Date:
December 01, 2022
Filing Date:
May 20, 2022
Export Citation:
Assignee:
BRL MEDICINE INC (CN)
International Classes:
C07K19/00; A61K39/00; A61P35/00; C07K14/725; C07K16/28; C12N5/10
Domestic Patent References:
| WO2020092854A2 | 2020-05-07 | |||
| WO2020148677A1 | 2020-07-23 |
Foreign References:
| CN107428829A | 2017-12-01 | |||
| CN110462038A | 2019-11-15 |
Other References:
LARREA, C. F. ET AL.: "Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma", BLOOD CANCER DISCOVERY, vol. 1, 30 September 2020 (2020-09-30), XP055847845, DOI: 10.1158/2643-3230.BCD-20-0020
E L SMITH, ET AL: "GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells", SCI. TRANSL. MED, vol. 11, no. 7746, 27 March 2019 (2019-03-27), pages 1 - 14, XP055665996, DOI: 10.1126/scitranslmed.aau7746
E L SMITH, ET AL: "GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells", SCI. TRANSL. MED, vol. 11, no. 7746, 27 March 2019 (2019-03-27), pages 1 - 14, XP055665996, DOI: 10.1126/scitranslmed.aau7746
Attorney, Agent or Firm:
SHANGHAI BESTFAMEIP INTELLECTUAL PROPERTY ATTORNEYS (CN)
Download PDF:
Previous Patent: LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
Next Patent: FLUORINE-SUBSTITUTED PYRIMIDOPYRIDINE COMPOUND AND USE THEREOF
Next Patent: FLUORINE-SUBSTITUTED PYRIMIDOPYRIDINE COMPOUND AND USE THEREOF